



CTS SCIENTIFIC PROGRAM 2019

Monday October 21, 2019, 11:00 – 17:30

Held in conjunction with CHEST Annual Meeting
Room 278-279, Ernest N. Morial Convention Center, 900
Convention Center Blvd
New Orleans, LA 70130

Program Chair: Dr. François Maltais

**11:00 – 11:20 Future Strategies for The Management of Non-Cystic Fibrosis
Bronchiectasis**

*Dr. Maeve Smith
University of Alberta*

Bronchiectasis is a complex and challenging condition with currently limited therapeutic options. This session will highlight a few of the challenges currently faced in the management of bronchiectasis. The talk will then focus on the therapies that are being developed and explored for potential future use in bronchiectasis, particularly anti-inflammatory strategies. At the end of this session, participants will be able to:

1. Identify some of the current challenges in the management of bronchiectasis.
2. Discuss the potential therapeutic targets for new therapies.
3. Understand the most recent trials exploring the role for novel agents in bronchiectasis.

**11:20 – 11:40 Understanding the Burden of Influenza, Clinical Outcomes, and
Effectiveness of Vaccination among People with COPD**

*Dr. Sunita Mulpuru
University of Ottawa*

People with COPD face heightened risks of death, critical illness, and hospitalization if they become infected with Influenza. Antiviral medications and influenza vaccination represent two strategies to improve the outcomes associated with influenza infection, yet antiviral prescription rates in hospitals are low and vaccination rates among people with COPD remain suboptimal. In this presentation, we will review and discuss recently published data on the effectiveness of influenza vaccination from a prospective cohort study in Canada involving more than 4000 hospitalized patients with COPD. We will also review the burden of influenza infection, associated clinical outcomes, and indications to use high-dose influenza vaccine among people with COPD. At the end of this session, participants will be able to:

1. Review the burden of influenza infection and the associated clinical outcomes among people with COPD
2. Understand the evidence supporting effectiveness of the Influenza vaccine among people with COPD
3. Discuss the evidence for 'high dose' influenza vaccine and current indications

11:40 – 12:00 Sleep-disordered breathing and neurodegenerative disorders

*Dr. Marta Kaminska
McGill University*

With an aging population, neurodegenerative disorders are on the rise and a major burden on individuals and health care systems. Recent studies suggest that OSA is a risk factor for stroke, mild cognitive impairment, Alzheimer's disease and Parkinson's disease. Prevention through treatment of risk factors is currently the main intervention for reducing the incidence of these disorders. Therefore, how obstructive sleep apnea affects brain health and whether its treatment can slow neurodegeneration are highly relevant questions. This session will focus on the aging brain and the link between obstructive sleep apnea, brain health, cognitive decline, dementia and neurodegeneration. At the end of this session, participants will be able to:

1. Describe epidemiologic evidence suggesting a link between OSA and neurodegenerative disorders.
2. Explain the proposed mechanisms whereby OSA can predispose to cognitive impairment.
3. Discuss the possible effects of OSA on manifestations of Parkinson's disease.

12:00 – 13:30 Lunch

13:30 – 14:30 Pro/Con Debate: Inhaled therapy on an as-needed basis is the way to go in the management of mild-moderate asthma

*Dr. Pierre Ernst
McGill University*

Pro: Dr. Richard Leigh | Con: Dr. Pierre Ernst

*Dr. Richard Leigh
University of Calgary*

This session will review the appropriateness of regular inhaled anti-inflammatory therapy in mild-moderate asthma in light of recent evidence and the emergence of biomarkers. At the end of this session, participants will be able to:

1. Discuss the role of inhaled anti-inflammatory therapy in mild to moderate asthma
2. Recognize heterogeneity of mild to moderate asthma
3. Review the CTS and GINA guidelines for the treatment of mild-moderate asthma

14:30 – 15:15 Break

15:15 – 15:45 Understanding health outcomes beyond the border: International comparisons in CF

*Dr. Anne Stephenson
University of Toronto*

This presentation will focus on how international comparisons in health outcomes using national registries can advance our understanding of health care delivery. I will discuss factors that influence survival statistics, present differences in CF-related health outcomes between Canada and the USA and identify factors that may be contributing to the survival gap. At the end of this session, participants will be able to:

1. Recognize the factors that impact survival statistics
2. Compare CF survival statistics between Canada and the US
3. Identify factors that may be contributing to the survival gap

15:45 – 16:15 **Translational medicine in pulmonary hypertension**

*Dr. Steeve Provencher
Université Laval*

The number of scientific publications related to PAH has increased exponentially during the last 2 decades, leading to significant advances in our understanding of the pathophysiology of the disease. Despite recent drug development, long-term prognosis in PAH remains unsatisfactory. Significant translational and therapeutic gaps between preclinical research and improved patients' outcomes thus remain. This lecture will overview the potential pitfalls in PAH preclinical research as well as efforts to improve translationality of preclinical findings and PAH patients' outcomes. At the end of this session, participants will be able to:

1. Recognize potential pitfalls in PAH preclinical research
2. Summarize recent recommendations to improve translational research in PAH
3. Describe how the implementation of high standards and methodological will foster the development of the next generation of PAH therapies

16:15 – 16:30 **Break**

16:30-17:30 **2019 CTS Honorary Lecture**

The evolution of asthma care: a 30 year perspective

*Dr. Mark Fitzgerald
University of British Columbia*

Thirty years ago, Canada was one of the first countries to convene an evidence-based review of the management of asthma. Since that time there have been improvements in the care of asthma and more recently the emergence of targeted therapies for severe asthma. In addition, there is a much greater appreciation of non-pharmacologic interventions especially asthma education. This presentation will review this evolution and identify future directions that are required at a national and international level. At the end of this session, participants will be able to:

1. Recognize the burden of both severe and uncontrolled asthma
2. Review the emergence of precision medicine and targeted treatment for severe asthma
3. Discuss the importance of recognizing the role of non-pharmacologic interventions in asthma

18:30 – 20:00 **CTS Members' Reception (*by invitation*)**

New Orleans Marriott, 555 Canal Street, New Orleans, LA